Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bio-Path Holdings, Inc.

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces Publication in Biomedicines
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Provides Clinical Update and Expansion Plans
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Reports First Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Expands Global Patent Portfolio
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Provides 2024 Clinical and Operational Update
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Reports Full Year 2023 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.